Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves’ disease
Authors:
Open Access
- 1 June 2007
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 156 (6) , 623-630
Abstract
Objective: Although Graves’ disease is considered an autoantibody-mediated, T-helper 2 (Th2)-dominant disease, Th1-dominance may prevail in its initial phase. We longitudinally investigated Th1/Th2 balance in untreated hyperthyroid patients with Graves’ disease after treatment of methimazole (MMI), an antithyroid drug. Design: University clinic outpatients were studied prospectively. Patients: Subjects included 23 untreated hyperthyroid patients with Graves’ disease and 17 age-matched control subjects. Methods: Before and after treatment, we measured Th1- and Th2-associated chemokine receptors (CXCR)3 and CCR4, on peripheral blood lymphocytes using flow cytometry, as well as plasma concentrations of their ligands, interferon-inducible protein (IP)-10 and thymus and activation-regulated chemokine (TARC). Results: The percentage of CXCR3-expressing cells among CD4+T lymphocytes and plasma IP-10 was significantly higher in hyperthyroid Graves’ disease patients than in controls. At 12 and 24 weeks after initiation of MMI, percentage of CXCR3-expressing CD4+T lymphocytes had decreased significantly, while the percentage of CCR4-expressing CD4+T lymphocytes had increased significantly at 24 weeks. The CXCR3/CCR4 ratio had decreased significantly at 24 weeks. Plasma concentrations of IP-10 had decreased significantly at 12 and 24 weeks. Plasma concentrations of TARC also had decreased significantly at 24 weeks. Conclusions: In hyperthyroid patients with Graves’ disease in the active phase, Th1 cells rather than Th2 cells predominated among peripheral blood lymphocytes. After initiation of MMI, an ongoing transition from Th1 to Th2 dominance occurred.Keywords
This publication has 24 references indexed in Scilit:
- Serum levels of the interferon-γ-inducible α chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomyBritish Journal of Surgery, 2006
- Cellular immune responses in autoimmune thyroid diseaseClinical Endocrinology, 2004
- Detection and localization of chemokine gene expression in autoimmune thyroid diseaseClinical Endocrinology, 2003
- Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthmaJournal of Allergy and Clinical Immunology, 2002
- Graves’ disease is associated with an altered CXCR3 and CCR5 expression in thyroid-derived compared to peripheral blood lymphocytesClinical and Experimental Immunology, 2002
- CCR4+ memory CD4+ T lymphocytes are increased in peripheral blood and lesional skin from patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2001
- Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines.Journal of Clinical Investigation, 1995
- Activated Naive CD4 + Peripheral Blood T Cells in Autoimmune Thyroid DiseaseThyroid®, 1995
- TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional PropertiesAnnual Review of Immunology, 1989
- Induction of Circulating Activated Suppressor-like T Cells by Methimazole Therapy for Graves' DiseaseNew England Journal of Medicine, 1987